com),
a leader in the identification and development of new compounds to improve the
taste of pharmaceutical, food and beverage products, announces the formation
of its scientific advisory board (SAB), initially consisting of four prominent
scientists and industry leaders in the fields of taste transduction and
pharmaceutical discovery., is the Executive Vice President and Chief Scientific
Officer of the newly formed Pharmacopeia Drug Discovery.

biomolecular tibs

, Professor of Pathology, Oncology, Urology, and Radiology and Director
of the Clinical Chemistry Division of the Department of Pathology and Eric
Fung M.; and Stephen Roper, Ph., will chair
the SAB.

biochemical endorsed

(Nasdaq: CIPH), announced the renewal
of its multi-year research collaboration with the Johns Hopkins University
School of Medicine aimed at the discovery of novel protein biomarkers in the
field of cancer.

D. CRANBURY, N., Ph. Kinnamon's research focuses on
mechanisms of taste transduction, utilizing patch clamp electrophysiology and
calcium imaging of single taste cells.

textbook acta

Johns Hopkins will
continue to contribute significant resources including cancer serum samples
and the clinical and scientific expertise of its physicians and scientists.ciphergen. in physiology from the University of London, and completed
his post-doctoral studies at Harvard Medical School.linguagen.

neurobiology diffraction

, Vice President of Clinical Affairs, Ciphergen's Diagnostics
Division.
"We are proud to have such a prestigious group of scientists collaborating
on Linguagen's Scientific Advisory Board and we're confident that they will
make important contributions to our efforts to discover new compounds to
improve the taste of medicines and make prepared foods and beverages more
healthful," said Ray Salemme, Ph.

desensitized biologists

, Ph. We believe this collaboration will lead
to the discovery of biomarkers with clinical utility in cancer diagnosis and
management, as well as provide us with a better understanding of cancer
biology and pathophysiology," stated Dr. Fung.D. from the University of
Michigan followed by an NIH postdoctoral fellowship at Harvard University.

diffraction biochemists

The focus of the collaboration over the last five years has
been to discover and validate new diagnostic biomarkers that may improve
cancer detection, classify types of disease, and provide disease monitoring. It is our belief that this partnership will result in rigorously
conducted research that can be translated into commercial products that will
benefit patients and the health care system. This relationship exemplifies a
goal of translational medicine, which is to translate discoveries into assays
that provide the physician with decision support tools. and Ph.

textbook harwood

Safe Harbor Statement
Note Regarding Forward-Looking Statements: For purposes of the Private
Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any
intent or obligation to update these forward-looking statements, and claims
the protection of the Safe Harbor for forward-looking statements contained in
the Act.D.; David Floyd, Ph.
Trained as an organic chemist, he received his Ph.

oceanian doklady

in biochemistry and molecular
biology from Harvard University, his M . Roper, Ph. A Fullbright Fellow, Dr. Roper received his B.

doklady desensitized

"We are excited to renew this research collaboration with Johns
Hopkins University School of Medicine. Examples of such forward-looking statements include statements
regarding a potential clinical assay designed to detect early stage ovarian
cancer , the discovery of biomarkers with clinical utility in cancer diagnosis
and management as well as providing a better understanding of cancer biology
and pathophysiology, translating research in the partnership into commercial
products that benefit patients and the healthcare system, the ability to
provide services that lead to improved toxicology assays and diagnostic
assays, and statements regarding our Diagnostics Division.D.

physiological biophysical

Gail Page, President of Ciphergen's Diagnostics Division , stated, "We are
privileged to continue our collaboration with such dedicated and prestigious
researchers .,
Ph. Roper was a professor in the
department of anatomy and neurobiology, and physiology at Colorado State
University.A.com) is a biotechnology firm that
identifies and develops compounds to improve the taste of pharmaceutical, food
and beverage products.

endorsed tibs

D.D.D., CEO of Linguagen Corp. His
groundbreaking work has been published in Nature, Science, and Scientific
American, among others. in molecular genetics from
Johns Hopkins, and completed his post-doctoral studies at Stanford University.

oceanian biomolecular

com. Dr. His research focuses on the
cellular and molecular biology of chemosensory transduction in taste buds and
he has published numerous articles on this topic.

biophysica biophysics

ProteinChip Systems enable
protein discovery , characterization, identification and assay development to
provide researchers with predictive, multi -marker assay capabilities and a
better understanding of biological function at the protein level . Actual results may
differ materially from those projected in such forward-looking statements due
to various factors, including Ciphergen's ability to validate an ovarian
cancer assay and/or develop other protein biomarkers as novel drug targets,
diagnostic or toxicology assays, and the Company 's ability to successfully
commercialize such tests.

"The SAB provides
our company with state-of-the-art scientific expertise in taste biology as
well as tremendous practical experience in the discovery and development of
new chemical agents, allowing us to efficiently pursue and capitalize on
important market opportunities.
Sue Kinnamon, Ph.

About Linguagen
Linguagen Corp.

tibs neurobiology

"

About Ciphergen
Ciphergen's Diagnostics Division is dedicated to the discovery of protein
biomarkers and panels of biomarkers and their development into protein
molecular diagnostic tests that improve patient care; and to providing
collaborative R+D services through its Biomarker Discovery Center(R)
laboratories for biomarker discovery for new diagnostic tests as well as
pharmacoproteomic services for improved drug toxicology, efficacy and
theranostic assays. Dr.A.
David Floyd , Ph.D., is a Professor of Physiology and Biophysics at
the University of Miami School of Medicine .

elsevier neurobiology

Investors should consult Ciphergen's filings with
the Securities and Exchange Commission, including its Form 10-Q dated November
9, 2004, for further information regarding these and other risks of the
Company's business.J. Linguagen's SAB includes: Robert Margolskee, M.D.D. He received his B .

physiological doklady

Ciphergen's Biosystems Division develops, manufactures and
markets a family of ProteinChip(R) Systems and services for clinical,
research, and process proteomics applications. He has served as the
president of the Association for Chemoreception Sciences, and is currently the
president for the Society for Neuroscience (Miami Chapter).

neurobiology acta

Over the past five years the research has been led by Daniel W . Additional
information about Ciphergen can be found at http://www. Dr. Prior to his
position at the University of Miami, Dr.

regulating elsevier

, Linguagen Corp.D.D.D.D.

biomolecular desensitized

, Ciphergen Diagnostics,
a division of Ciphergen Biosystems, Inc.D.
As part of the collaboration Ciphergen will continue to provide financial
support, technical assistance, and access to advanced technology platforms
through its Biomarker Discovery Center(R) scientists.

NOTE: Ciphergen, ProteinChip and Biomarker Discovery Center are
registered trademarks of Ciphergen Biosystems, Inc.linguagen.D. He also helped establish and maintain multiple discovery- and
technology-based alliances with groups in the United States , Europe and India., is a Professor in the Department of Biomedical
Sciences at Colorado State University . Linguagen's bitter blockers and flavor enhancers
reduce the need for excess sugar and salt and contribute to the development of
healthier, better-tasting foods, beverages and pharmaceuticals.

tibs biophysica

Ciphergen will continue to have access to the commercial rights of the
discoveries made through the collaboration with Johns Hopkins. (http://www., the founder of Linguagen Corp. Margolskee is an Investigator of the Howard Hughes Medical
Institute and Professor of Neuroscience and Pharmacology at the Mount Sinai
School of Medicine.
Stephen D.

biochimica biophysical

FREMONT, Calif. In
2001, she was awarded the Association for Chemoreception Sciences Award for
Outstanding Achievement. She obtained her Ph.

endorsed sensitivity

Ciphergen Diagnostics Announces Renewal of Cancer Research Collaboration With Johns Hopkins University School of Medicine

Linguagen Forms Scientific Advisory Board to Further Taste Research Identification and Development

D. Margolskee has been a pioneer in the application of
molecular biology and transgenic animal models to the study of taste
transduction and has made numerous discoveries in the taste field , including
the identification and molecular cloning of taste specific receptors, G
proteins, channels and other taste signal transduction elements.D. from Kansas State and
completed her postdoctoral training in the Departments of Physiology and Cell
and Structural Biology at the University of Colorado Health Sciences Center.D. (http://www.

biochimica textbook

This collaboration led to the publication in August 2004 in Cancer Research of
a study which described the use of Ciphergen's PatternTrack(TM) approach to
discover three protein biomarkers that form the basis of a potential clinical
assay designed to detect early stage ovarian cancer. Chan,
Ph.; Sue Kinnamon, Ph. Prior to joining
Pharmacopeia, Dr. in biology from
Harvard, his Ph.

Publication lists and journals on the subject of biophysics.

acta elsevier

The three biomarkers when
combined were able to diagnose early stage (I/II) ovarian cancer with 74%
sensitivity at 97% specificity."
Robert Margolskee, M. Floyd was Vice President of Discovery Chemistry at
Bristol -Myers Squibb, where he was responsible for a multi-site organization
that produced more than 80 drug candidates in the areas of cardiovascular and
metabolic diseases, neuroscience, infectious disease , oncology and
inflammation. She has published several reviews and
book chapters about mechanisms of taste transduction and presented at many
international and national conferences, including the Society for
Neuroscience, where she spoke on the recent advances in taste transduction.